



# EMERGING IMMUNOTHERAPIES in **CANCER** 2<sup>ND</sup> EDITION

17<sup>TH</sup> SEPTEMBER 2020

The Emerging Immunotherapies in Cancer - II edition, Barcelona, Spain, 17/09/2020 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 4 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

9.30 h	Welcome	Leticia De Mattos, IrsiCaixa Research Institute, Barcelona
9.40 h	Opening lecture: immunotherapy goes local	Ignacio Melero, University of Navarra Clinic, Navarra

**TABLE I: Novel cancer immunotherapy approaches and biomarkers**

**CHAIR: Leticia De Mattos, IrsiCaixa Research Institute, Barcelona**

10.10 h	Immuno-oncology today in the clinics and in the context of other therapy	Caroline Robert, Institut Gustave Roussy, Paris, France
10.30 h	Update on Immunotherapy and Combinations in Urothelial Malignancies	Joaquim Bellmunt, Harvard Medical School, Boston, USA
10.50 h	Overall discussion	
11: 10 h	BREAK	

**TABLE II: Computation biology meets personalized immunotherapy**

**CHAIR: Ramon Alemany, Catalan Institute of Oncology – IDIBELL, Barcelona**

11:40 h	Computational biology: new trends to personalized immunotherapy of cancer	Francesca Finotello, Medizinische Universität Innsbruck, Austria
12.00 h	Neoantigens cancer vaccines to shape the immune system in the clinics	Leticia De Mattos, IrsiCaixa Research Institute, Barcelona
12.20 h	New data on CAR-T cell therapy	Manel Juan, Hospital Clínic de Barcelona
12.40 h	Overall discussion	
13.00 h	LUNCH	

**TABLE III: New perspectives: virus and cancer**

**CHAIR: Bonaventura Clotet, IrsiCaixa Research Institute. Barcelona**

14.00 h	Role of oncolytic viruses for cancer treatment		Ramon Alemany, Catalan Institute of Oncology – IDIBELL, Barcelona
14.20 h	Lessons learnt from Durvast trial: novel immunotherapy approaches for cancer patients		Rafael Rosell, Instituto Oncológico Dr. Rosell, Barcelona
14.40 h	Lessons learnt in the era of COVID-19 pandemic	When immunotherapy should be considered as a treatment option for patients and when it should not	Mariano Provencio, Hospital Puerta de Hierro, Madrid
15.00 h		COVID-19 infection in melanoma patients: results of the Spanish Melanoma Group register	Maria González Cao, Instituto Oncológico Dr. Rosell, Hospital Dexeus, Barcelona
15.20 h	Overall discussion		
15.40 h	Closing lecture: Immuno-oncology therapies in the clinic: what to expect for the next decade		Antoni Ribas, Jonsson Comprehensive Cancer Center David Geffen School of Medicine, University of California Los Angeles, USA

EMERGING  
IMMUNOTHERAPIES  
in **CANCER**  
2<sup>ND</sup> EDITION

Organized by



The workshop is possible thanks to  
the support of



Pfizer Inc.